Panoramic Capital LLC Purchases Shares of 7,681 Eli Lilly and Company (NYSE:LLY)

Panoramic Capital LLC acquired a new stake in Eli Lilly and Company (NYSE:LLY - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 7,681 shares of the company's stock, valued at approximately $5,930,000. Eli Lilly and Company accounts for approximately 3.2% of Panoramic Capital LLC's investment portfolio, making the stock its 4th biggest holding.

Other hedge funds also recently added to or reduced their stakes in the company. FPC Investment Advisory Inc. increased its position in shares of Eli Lilly and Company by 358.3% during the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock worth $45,000 after acquiring an additional 43 shares during the last quarter. Prudent Man Investment Management Inc. purchased a new stake in shares of Eli Lilly and Company during the fourth quarter worth about $48,000. Compass Financial Services Inc purchased a new stake in shares of Eli Lilly and Company during the fourth quarter worth about $50,000. Fiduciary Advisors Inc. purchased a new stake in shares of Eli Lilly and Company during the fourth quarter worth about $58,000. Finally, Bellwether Advisors LLC purchased a new stake in shares of Eli Lilly and Company during the fourth quarter worth about $66,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

LLY has been the subject of a number of research reports. Hsbc Global Res downgraded Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. Citigroup decreased their price target on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a research note on Tuesday, January 28th. Wells Fargo & Company reiterated an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. HSBC downgraded Eli Lilly and Company from a "buy" rating to a "reduce" rating and decreased their price target for the stock from $1,150.00 to $700.00 in a research note on Monday, April 28th. Finally, Truist Financial lifted their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. One analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $1,011.37.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. This represents a 14.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Price Performance

NYSE:LLY traded up $23.94 during midday trading on Friday, hitting $757.23. 4,632,057 shares of the stock were exchanged, compared to its average volume of 3,591,387. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53. The company has a market capitalization of $717.65 billion, a price-to-earnings ratio of 64.67, a P/E/G ratio of 1.40 and a beta of 0.48. The business has a 50-day moving average price of $799.17 and a two-hundred day moving average price of $807.15. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The firm had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. During the same period in the previous year, the firm earned $2.58 EPS. Eli Lilly and Company's revenue for the quarter was up 45.2% on a year-over-year basis. Sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be issued a $1.50 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 annualized dividend and a dividend yield of 0.79%. Eli Lilly and Company's dividend payout ratio is currently 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.